The functional role of ERK activity in esketamine's antidepressant effects.
Pharmacology, biochemistry, and behavior July 26, 2026 Peng Zhang, Mengyu Wu, Keke Zhang et al.
Esketamine has been approved for the treatment of treatment-resistant depression. However, there is an unmet clinical need to extend the duration of esketamine's action to reduce the high recurrence rate after drug withdrawal and the potential side effects of repeated esketamine use. Here, we found that increasing extracellular signal-regulated kinase (ERK) activity by pharmacologically...